Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait

Radium-223 is the 1st nuclide medicine from the group of alpha emitters, its use is associated with an increase in overall survival, a delay to bone complications and a significant improvement the quality of life, proven placebo-controlled randomized studies in patients with castration-resistant prostate cancer in the presence of bone metastases and no visceral ones. Perhaps the еarly use of radium-223 in combination with enzalutamide or abiraterone in castration-resistant prostate cancer patients with bone metastases, before the start of treatment with taxanes is reasonable.Today, the issue of embedding modern nuclide therapy in the accepted system of treating castration-resistant prostate cancer